Literature DB >> 6156843

Natural killer and killer cell activities in patients with primary immunodeficiencies or defects in immune interferon production.

M Lipinski, J L Virelizier, T Tursz, C Griscelli.   

Abstract

Natural cell-mediated cytotoxicity (NCMC) against K-562 target cells was explored in patients with various primary immunodeficiencies. (a) NCMC was present in 2 patients lacking detectable B cells. Conversely, NCMC was depressed in 2 patients with severe combined immunodeficiency presenting a normal number of circulating B cells. These data exclude a major role for B cells in NCMC. (b) NCMC was depressed mainly in patients with severe combined immunodeficiency or with defects affecting cellular immunity, which suggests a major role in NCMC for cells of T lineage. (c) Four patients with various clinical features associated with a lack of immune interferon production exhibited a strikingly depressed NCMC. Interferon thus appears as a major in vivo activator of natural killer (NK) cell activity. (d) Eight patients exhibiting a depressed NK cell activity had a normal killer (K) cell activity against L1210 cells in the presence of rabbit anti-L1210 antiserum. These data are consistent with the assumption that NK and K cell activity are mediated through two distinct cellular mechanisms.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6156843     DOI: 10.1002/eji.1830100405

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

1.  The DiGeorge sequence. II. Immunologic findings in partial and complete forms of the disorder.

Authors:  W Müller; H H Peter; H C Kallfelz; A Franz; C H Rieger
Journal:  Eur J Pediatr       Date:  1989-11       Impact factor: 3.183

2.  Dissociation between onset of natural killer E-rosette forming cells and of T3-positive cells following HLA-mismatched T cell depleted bone marrow transplantation.

Authors:  J P De Villartay; F Le Deist; C Griscelli; A Fischer
Journal:  Clin Exp Immunol       Date:  1987-02       Impact factor: 4.330

3.  Effects of activated T cells on natural killing.

Authors:  R A Knight; P Fitzharris
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

Review 4.  The biology of the human natural killer cell.

Authors:  J C Roder; H F Pross
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

5.  Depressed spontaneous cellular cytotoxicity associated with normal or enhanced antibody-dependent cellular cytotoxicity in patients on chronic haemodialysis.

Authors:  A M Badger; D B Bernard; B A Idelson; S R Cooperband
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

6.  Wiskott-Aldrich syndrome protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses.

Authors:  Jordan S Orange; Narayanaswamy Ramesh; Eileen Remold-O'Donnell; Yoji Sasahara; Louise Koopman; Michael Byrne; Francisco A Bonilla; Fred S Rosen; Raif S Geha; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

7.  Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia.

Authors:  E Vilmer; G M Lenoir; J L Virelizier; C Griscelli
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

8.  Antibody-dependent cellular cytotoxicity (K) and natural killing (NK) in B-suppressed germ-free nude rats.

Authors:  D Chassoux; J P Kolb; H Bazin; I C MacLennan
Journal:  Immunology       Date:  1983-11       Impact factor: 7.397

9.  Studies of the function of natural killer-interferon system in patients with Sjögren syndrome.

Authors:  N Minato; A Takeda; S Kano; F Takaku
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

10.  Intraepithelial lymphocytes of human gut: isolation, characterisation and study of natural killer activity.

Authors:  N Cerf-Bensussan; D Guy-Grand; C Griscelli
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.